{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"5.6","value":"4.2"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"3.8","value":"2.9"},{"groupId":"OG002","lowerLimit":"0.9","upperLimit":"0.9","value":"0.9"},{"groupId":"OG003","lowerLimit":"0.6","upperLimit":"9.2","value":"2.0"},{"groupId":"OG004","lowerLimit":"0.6","upperLimit":"9.7","value":"3.8"},{"groupId":"OG005","lowerLimit":"0.5","upperLimit":"5.7","value":"1.9"},{"groupId":"OG006","lowerLimit":"2.1","upperLimit":"7.5","value":"3.8"},{"groupId":"OG007","lowerLimit":"0.5","upperLimit":"3.8","value":"3.7"},{"groupId":"OG008","lowerLimit":"0.5","upperLimit":"3.8","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"}],"units":"Participants"}],"description":"Time to best response is defined as the time from the date of the first dose to the date of the first occurrence of best response according to the following hierarchical order: CR, CRi/CRp, PR, mCR (for MDS) / MLFS (for AML) based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator assessment.","dispersionType":"Full Range","groups":[{"description":"Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 1 Dose Escalation: Enasidenib 50 mg"},{"description":"Participants received enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG001","title":"Phase 1 Dose Escalation: Enasidenib 60 mg"},{"description":"Participants received enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG002","title":"Phase 1 Dose Escalation: Enasidenib 75 mg"},{"description":"Participants received enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG003","title":"Phase 1 Dose Escalation: Enasidenib 100 mg"},{"description":"Participants received enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG004","title":"Phase 1 Dose Escalation: Enasidenib 150 mg"},{"description":"Participants received enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG005","title":"Phase 1 Dose Escalation: Enasidenib 200 mg"},{"description":"Participants received enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG006","title":"Phase 1 Dose Escalation: Enasidenib 300 mg"},{"description":"Participants received enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG007","title":"Phase 1 Dose Escalation: Enasidenib 450 mg"},{"description":"Participants received enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG008","title":"Phase 1 Dose Escalation: Enasidenib 650 mg"}],"paramType":"MEDIAN","populationDescription":"Participants who received at least one dose of study treatment in Phase 1 Dose Escalation and who had an objective response. Participants were grouped according to assigned total daily dose.","reportingStatus":"POSTED","timeFrame":"Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).","title":"Phase 1 Dose Escalation: Time to Best Response by Total Daily Dose","type":"SECONDARY","unitOfMeasure":"months"}